Axogen Inc vs Oxford Lane Capital Corp — how do they compare? Axogen Inc trades at $38.5 (market cap $2.06B), while Oxford Lane Capital Corp trades at $9.16 (market cap $891.54M). The key difference: Axogen Inc is far larger — about 2.3× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 26.29% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | OXLC | |
|---|---|---|
Market Cap | $2.06B | $891.54M |
Sector | Technology | Financials |
52-Week High | $46.19 | $20.80 |
52-Week Low | $11.28 | $8.15 |
Enterprise Value | $1.98B | — |
Dividend Yield | — | 26.29% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
OXLC trades at $9.19, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI levels. The company reported a net income margin of 100.85% for 2025, but earnings misses and a sharp revenue decline to -$580M in 2026 highlight volatility. Recent news includes dividend declarations and a net asset value update from Oxford Lane Capital on June 15, 2026.
Outlook is cautious due to inconsistent earnings and high yield sustainability concerns. Risks include NAV decay and competitive pressures, while opportunities lie in dividend income. Analyst consensus is split, with 50% buy ratings but significant sell coverage citing fund performance issues.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →